IL326463A - צורות גבישיות של מעכב pi3k ושימושים בו - Google Patents
צורות גבישיות של מעכב pi3k ושימושים בוInfo
- Publication number
- IL326463A IL326463A IL326463A IL32646326A IL326463A IL 326463 A IL326463 A IL 326463A IL 326463 A IL326463 A IL 326463A IL 32646326 A IL32646326 A IL 32646326A IL 326463 A IL326463 A IL 326463A
- Authority
- IL
- Israel
- Prior art keywords
- degrees
- peak
- crystalline form
- methylbenzofuran
- aminopyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363532700P | 2023-08-15 | 2023-08-15 | |
| PCT/US2024/042221 WO2025038698A1 (en) | 2023-08-15 | 2024-08-14 | Crystalline forms of a pi3k inhibitor and uses of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL326463A true IL326463A (he) | 2026-04-01 |
Family
ID=92632772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL326463A IL326463A (he) | 2023-08-15 | 2024-08-14 | צורות גבישיות של מעכב pi3k ושימושים בו |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4762049A1 (he) |
| KR (1) | KR20260053331A (he) |
| CN (1) | CN122029161A (he) |
| AR (1) | AR133554A1 (he) |
| AU (1) | AU2024323620A1 (he) |
| CL (1) | CL2026000446A1 (he) |
| CO (1) | CO2026001466A2 (he) |
| CR (1) | CR20260057A (he) |
| DO (1) | DOP2026000038A (he) |
| IL (1) | IL326463A (he) |
| MX (1) | MX2026001800A (he) |
| PE (1) | PE20260820A1 (he) |
| TW (1) | TW202509025A (he) |
| WO (1) | WO2025038698A1 (he) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023014819A (es) | 2021-06-14 | 2024-03-21 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer. |
| IL320537A (he) * | 2022-10-31 | 2025-06-01 | Scorpion Therapeutics Inc | טיפול משולב לטיפול בסרטן |
-
2024
- 2024-08-14 KR KR1020267007521A patent/KR20260053331A/ko active Pending
- 2024-08-14 WO PCT/US2024/042221 patent/WO2025038698A1/en not_active Ceased
- 2024-08-14 PE PE2026000278A patent/PE20260820A1/es unknown
- 2024-08-14 AU AU2024323620A patent/AU2024323620A1/en active Pending
- 2024-08-14 CN CN202480065668.6A patent/CN122029161A/zh active Pending
- 2024-08-14 CR CR20260057A patent/CR20260057A/es unknown
- 2024-08-14 TW TW113130461A patent/TW202509025A/zh unknown
- 2024-08-14 IL IL326463A patent/IL326463A/he unknown
- 2024-08-14 EP EP24765277.9A patent/EP4762049A1/en active Pending
- 2024-08-15 AR ARP240102160A patent/AR133554A1/es unknown
-
2026
- 2026-02-09 CO CONC2026/0001466A patent/CO2026001466A2/es unknown
- 2026-02-11 DO DO2026000038A patent/DOP2026000038A/es unknown
- 2026-02-13 CL CL2026000446A patent/CL2026000446A1/es unknown
- 2026-02-13 MX MX2026001800A patent/MX2026001800A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20260820A1 (es) | 2026-04-15 |
| TW202509025A (zh) | 2025-03-01 |
| MX2026001800A (es) | 2026-03-02 |
| KR20260053331A (ko) | 2026-04-21 |
| EP4762049A1 (en) | 2026-06-24 |
| CL2026000446A1 (es) | 2026-05-15 |
| WO2025038698A9 (en) | 2025-06-05 |
| CR20260057A (es) | 2026-03-09 |
| CN122029161A (zh) | 2026-05-12 |
| AR133554A1 (es) | 2025-10-08 |
| WO2025038698A1 (en) | 2025-02-20 |
| DOP2026000038A (es) | 2026-05-31 |
| AU2024323620A1 (en) | 2026-02-19 |
| CO2026001466A2 (es) | 2026-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310234A (he) | מלחים ותצורות מצב מוצק של תרכובת מעכב kif18a | |
| AU2024325407A1 (en) | Benzopyridinones and benzopyrimidinones as pi3k inhibitors | |
| IL326137A (he) | מעכבי pi3k | |
| AU2024314618A1 (en) | Pi3k inhibitors and use thereof | |
| IL321357A (he) | מעכבי kif18a ושימושים שלהם | |
| IL321053A (he) | צורות גבישיות של מעכב her2 | |
| EP4244231A4 (en) | CRYSTALLINE SOLID MEGLUMIN SALT INHIBITOR OF BCL AND METHOD OF PREPARING AND USING THE SAME | |
| IL325861A (he) | צורות גבישיות של מעכב מנין | |
| IL321007A (he) | צורות גבישיות של מעכב פיפרידין של תפקוד slc6a19 | |
| EP4181921A4 (en) | CRYSTALLINE FORMS OF A SELECTIVE C-KIT KINASE INHIBITOR | |
| CA3264917A1 (en) | KIF18A INHIBITORS AND THEIR USES | |
| AU2024395016A1 (en) | Solid state forms of a kinase inhibitor | |
| IL319006A (he) | צורות גבישיות של מעכב pcsk9, הרכבים ושימושים | |
| IL305791A (he) | מלח וצורות מוצקות של מעכב קינאז | |
| HK40121198A (en) | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof | |
| AU2021368138A9 (en) | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof | |
| HUE073161T2 (hu) | Jak-gátló kristályos formája és alkalmazása | |
| HK40128961A (zh) | Parp1抑制剂的结晶形式 | |
| HK40109581A (en) | Salts and solid state forms of a kif18a inhibitor compound | |
| CA3288716A1 (en) | Crystalline forms of a ras inhibitor | |
| HK40117256A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| HK40086278A (en) | Crystalline forms of a tyk2 inhibitor | |
| HK40091715A (en) | Crystalline forms of a cd73 inhibitor and uses thereof | |
| IL326563A (he) | צורות גבישיות של מעכב bet | |
| GB202101735D0 (en) | Solid forms of a plasma kallikrein inhibitor and salts thereof |